Clinical Trial Update: Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting safety and efficacy of IBI306 in Chinese subjects with non-familial hypercholesterolemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• IBI306

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED